|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Philippe Pouletty M.D., Ph.D.||Founder & Director||N/D||N/D||1958|
|Mr. Marc M. P. de Garidel M.B.A.||CEO & Interim Chair of Board||N/D||N/D||1958|
|Mr. Didier Blondel||EVP, CFO & Board Secretary||N/D||N/D||1963|
|Mr. Didier Scherrer Ph.D.||Chief Scientific Officer||N/D||N/D||1969|
|Mr. Patrick Malloy||Senior Vice President of Investor Relations||N/D||N/D||N/D|
|Ms. Ida Hatoum||Chief People Officer||N/D||N/D||N/D|
|Mr. Pierre Courteille M.B.A.||Chief Business Officer||N/D||N/D||1968|
|Mr. Jérôme Denis||Executive Vice President of Process Development & Manufacturing||N/D||N/D||N/D|
|Mr. Sheldon Sloan M.D.||Chief Medical Officer||N/D||N/D||1958|
|Mr. Michael Ferguson B.S., M.B.A.||Chief Commercial Officer||N/D||N/D||1977|
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
L'ISS Governance QualityScore di ABIVAX Société Anonyme al 1 dicembre 2023 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 10.